Cord Blood Stem and Progenitor Cells

Hal Broxmeyer, Edward Srour, Christie Orschell, David Ingram, Scott Cooper, P. Artur Plett, Laura E. Mead, Mervin Yoder

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Cord blood has served as a source of hematopoietic stem and progenitor cells for successful repopulation of the blood cell system in patients with malignant and nonmalignant disorders. It was information on these rare immature cells in cord blood that led to the first use of cord blood for transplantation. Further information on these cells and how they can be manipulated both in vitro and in vivo will likely enhance the utility and broadness of applicability of cord blood for treatment of human disease. This chapter reviews information on the clinical and biological properties of hematopoietic stem and progenitor cells, as well as the biology of endothelial progenitor cells, and serves as a source for the methods used to detect and quantitate these important functional cells. Specifically, methods are presented for enumerating human cord blood myeloid progenitor cells, including granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM or CFU-Mix) progenitors, and their replating potential; hematopoietic stem cells, as assessed in vitro for long-term culture-initiating cells (LTC-ICs), cobblestone area-forming cells (CAFCs), and myeloid-lymphoid-initiating cells (ML-ICs), and as assessed in vivo for nonobese diabetic (NOD)/severe combined immunodeficient (SCID) mouse repopulating cells (SRCs); and high and low proliferative potential endothelial progenitor cells (EPCs).

Original languageEnglish
Pages (from-to)439-473
Number of pages35
JournalMethods in Enzymology
Volume419
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
Fetal Blood
Blood Cells
Myeloid Progenitor Cells
Blood
Stem Cells
Endothelial cells
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
SCID Mice
Myeloid Cells
Granulocytes
Macrophages
Stem cells
Cell culture
Cell Culture Techniques
Transplantation
Lymphocytes
Cells
Endothelial Progenitor Cells

ASJC Scopus subject areas

  • Biochemistry

Cite this

Cord Blood Stem and Progenitor Cells. / Broxmeyer, Hal; Srour, Edward; Orschell, Christie; Ingram, David; Cooper, Scott; Plett, P. Artur; Mead, Laura E.; Yoder, Mervin.

In: Methods in Enzymology, Vol. 419, 2006, p. 439-473.

Research output: Contribution to journalArticle

@article{0b2973f6a3814a3a8ca60db85f8d47a7,
title = "Cord Blood Stem and Progenitor Cells",
abstract = "Cord blood has served as a source of hematopoietic stem and progenitor cells for successful repopulation of the blood cell system in patients with malignant and nonmalignant disorders. It was information on these rare immature cells in cord blood that led to the first use of cord blood for transplantation. Further information on these cells and how they can be manipulated both in vitro and in vivo will likely enhance the utility and broadness of applicability of cord blood for treatment of human disease. This chapter reviews information on the clinical and biological properties of hematopoietic stem and progenitor cells, as well as the biology of endothelial progenitor cells, and serves as a source for the methods used to detect and quantitate these important functional cells. Specifically, methods are presented for enumerating human cord blood myeloid progenitor cells, including granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM or CFU-Mix) progenitors, and their replating potential; hematopoietic stem cells, as assessed in vitro for long-term culture-initiating cells (LTC-ICs), cobblestone area-forming cells (CAFCs), and myeloid-lymphoid-initiating cells (ML-ICs), and as assessed in vivo for nonobese diabetic (NOD)/severe combined immunodeficient (SCID) mouse repopulating cells (SRCs); and high and low proliferative potential endothelial progenitor cells (EPCs).",
author = "Hal Broxmeyer and Edward Srour and Christie Orschell and David Ingram and Scott Cooper and Plett, {P. Artur} and Mead, {Laura E.} and Mervin Yoder",
year = "2006",
doi = "10.1016/S0076-6879(06)19018-7",
language = "English",
volume = "419",
pages = "439--473",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cord Blood Stem and Progenitor Cells

AU - Broxmeyer, Hal

AU - Srour, Edward

AU - Orschell, Christie

AU - Ingram, David

AU - Cooper, Scott

AU - Plett, P. Artur

AU - Mead, Laura E.

AU - Yoder, Mervin

PY - 2006

Y1 - 2006

N2 - Cord blood has served as a source of hematopoietic stem and progenitor cells for successful repopulation of the blood cell system in patients with malignant and nonmalignant disorders. It was information on these rare immature cells in cord blood that led to the first use of cord blood for transplantation. Further information on these cells and how they can be manipulated both in vitro and in vivo will likely enhance the utility and broadness of applicability of cord blood for treatment of human disease. This chapter reviews information on the clinical and biological properties of hematopoietic stem and progenitor cells, as well as the biology of endothelial progenitor cells, and serves as a source for the methods used to detect and quantitate these important functional cells. Specifically, methods are presented for enumerating human cord blood myeloid progenitor cells, including granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM or CFU-Mix) progenitors, and their replating potential; hematopoietic stem cells, as assessed in vitro for long-term culture-initiating cells (LTC-ICs), cobblestone area-forming cells (CAFCs), and myeloid-lymphoid-initiating cells (ML-ICs), and as assessed in vivo for nonobese diabetic (NOD)/severe combined immunodeficient (SCID) mouse repopulating cells (SRCs); and high and low proliferative potential endothelial progenitor cells (EPCs).

AB - Cord blood has served as a source of hematopoietic stem and progenitor cells for successful repopulation of the blood cell system in patients with malignant and nonmalignant disorders. It was information on these rare immature cells in cord blood that led to the first use of cord blood for transplantation. Further information on these cells and how they can be manipulated both in vitro and in vivo will likely enhance the utility and broadness of applicability of cord blood for treatment of human disease. This chapter reviews information on the clinical and biological properties of hematopoietic stem and progenitor cells, as well as the biology of endothelial progenitor cells, and serves as a source for the methods used to detect and quantitate these important functional cells. Specifically, methods are presented for enumerating human cord blood myeloid progenitor cells, including granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM or CFU-Mix) progenitors, and their replating potential; hematopoietic stem cells, as assessed in vitro for long-term culture-initiating cells (LTC-ICs), cobblestone area-forming cells (CAFCs), and myeloid-lymphoid-initiating cells (ML-ICs), and as assessed in vivo for nonobese diabetic (NOD)/severe combined immunodeficient (SCID) mouse repopulating cells (SRCs); and high and low proliferative potential endothelial progenitor cells (EPCs).

UR - http://www.scopus.com/inward/record.url?scp=33751405576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751405576&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(06)19018-7

DO - 10.1016/S0076-6879(06)19018-7

M3 - Article

C2 - 17141066

AN - SCOPUS:33751405576

VL - 419

SP - 439

EP - 473

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

ER -